Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Partially-blinded, Placebo-controlled, Ascending Sequential Dose Groups, Single Dose Study of the Safety, Tolerability and Pharmacokinetics of CRV431, Alone and In Combination With Tenofovir Disoproxil Fumarate in Healthy Subjects, With a Pilot Study of Multiple Ascending Sequential Doses in Healthy Volunteer Subjects

NCT03596697 is registered in ClinicalTrials.gov with Hepion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03596697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03596697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Partially-blinded, Placebo-controlled, Ascending Sequential Dose Groups, Single Dose Study of the Safety, Tolerability and Pharmacokinetics of CRV431, Alone and In Combination With Tenofovir Disoproxil Fumarate in Healthy Subjects, With a Pilot Study of Multiple Ascending Sequential Doses in Healthy Volunteer Subjects
Lead sponsor
Hepion Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 9, 2019
Completion date
June 4, 2021
Enrollment
92 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, infectious disease, liver diseases